BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 9128319)

  • 1. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
    Bianchi Porro G; Lazzaroni M; Petrillo M
    Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.
    Raskin JB; White RH; Jaszewski R; Korsten MA; Schubert TT; Fort JG
    Am J Gastroenterol; 1996 Feb; 91(2):223-7. PubMed ID: 8607484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients.
    Miglioli M; Bianchi Porro G; Vaira D; Menegatti M; Brunetti G; Petrillo M; Ardizzone S; Frizziero L; Montrone F; Grandinetti G
    Am J Gastroenterol; 1996 Nov; 91(11):2367-71. PubMed ID: 8931419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Misoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agents].
    Delmas PD; Lambert R; Capron MH
    Rev Rhum Ed Fr; 1994 Feb; 61(2):126-31. PubMed ID: 7920500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs.
    Dajani EZ; Agrawal NM
    Dig Dis; 1995 Jan; 13 Suppl 1():48-61. PubMed ID: 7697902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
    Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI
    N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diclofenac/misoprostol: the European clinical experience.
    McKenna F
    J Rheumatol Suppl; 1998 May; 51():21-30. PubMed ID: 9596551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic efficacy of misoprostol in peptic ulcer disease.
    Watkinson G; Hopkins A; Akbar FA
    Postgrad Med J; 1988; 64 Suppl 1():60-77. PubMed ID: 3138682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of misoprostol's clinical utility for gastric/duodenal ulcers seen under long-term use of non-steroidal anti-inflammatory drugs (NSAID)--I. Evaluation of mucosal prophylactic effects by a placebo-controlled double blind comparative study].
    Shiokawa Y; Nobunaga M; Saito T; Sakita T; Miwa T; Nakamura K; Gunji A; Aoki K
    Ryumachi; 1991 Oct; 31(5):554-71. PubMed ID: 1767349
    [No Abstract]   [Full Text] [Related]  

  • 13. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
    Hawkey CJ; Karrasch JA; SzczepaƱski L; Walker DG; Barkun A; Swannell AJ; Yeomans ND
    N Engl J Med; 1998 Mar; 338(11):727-34. PubMed ID: 9494149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.
    Koch M; Dezi A; Ferrario F; Capurso I
    Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol.
    Koch M
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S54-62. PubMed ID: 10379471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
    Bocanegra TS; Weaver AL; Tindall EA; Sikes DH; Ball JA; Wallemark CB; Geis GS; Fort JG
    J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
    Geis GS; Stead H; Wallemark CB; Nicholson PA
    J Rheumatol Suppl; 1991 Mar; 28():11-4. PubMed ID: 1903808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage.
    Valentini M; Cannizzaro R; Poletti M; Bortolussi R; Fracasso A; Testa V; Sozzi M; Fornasarig M; Bortoluzzi F; Grazioli I
    J Clin Oncol; 1995 Oct; 13(10):2637-42. PubMed ID: 7595718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study.
    Bianchi Porro G; Lazzaroni M; Petrillo M; Manzionna G; Montrone F; Caruso I
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):43-7. PubMed ID: 9615264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.